Separation Science Careers: Innovation & Future Jobs

AstraZeneca’s Jennifer Kingston, a driving force behind cutting-edge purification technologies and a champion of scientific apprenticeships, has been awarded the Royal Society of Chemistry’s 2025 Technical Excellence Prize. While she modestly attributes it to “getting a pat on the back,” Kingston’s recognition signals a broader shift within the pharmaceutical industry: a growing emphasis on sustainable chemistry, advanced analytical techniques, and innovative workforce development. This isn’t simply about celebrating an individual achievement; it’s about recognizing the strategies that will define the next generation of drug discovery.

Challenging Chemistry, Delivering Results

Kingston’s career trajectory, from tracking water pollution to pioneering purification methods for oncology drugs, underscores a common theme: adaptability and a relentless curiosity. Her initial foray into pharmaceuticals was sparked by the story of Viagra – a reminder that serendipity often plays a role in scientific breakthroughs, but that rigorous analytical chemistry is essential to capitalize on those moments. The pharmaceutical industry, facing increasing pressure to deliver novel therapies faster and more efficiently, is increasingly reliant on specialists like Kingston who can bridge the gap between initial discovery and scalable production.

Her embrace of supercritical fluid chromatography (SFC) is particularly noteworthy. SFC, utilizing supercritical carbon dioxide, offers a greener alternative to traditional solvent-based chromatography, reducing waste and environmental impact. This aligns with growing regulatory scrutiny and consumer demand for sustainable manufacturing practices. The fact that Kingston initially faced resistance to adopting SFC – and overcame it through persistence and demonstrable results – speaks to the challenges of implementing new technologies within established organizations. It also highlights the importance of strong technical leadership.

From Apprentices to Scientists: Building the Future Pipeline

Perhaps Kingston’s most impactful contribution lies in establishing AstraZeneca’s degree apprenticeship program. This initiative directly addresses the critical shortage of skilled scientists and technicians in the pharmaceutical sector. By providing hands-on training and mentorship, the program not only creates a pipeline of talent but also fosters a culture of continuous learning and innovation. The success stories emerging from the program – apprentices becoming teachers and senior scientists – demonstrate the transformative potential of this approach. This is particularly relevant as the industry grapples with an aging workforce and increasing competition for talent.

The Forward Look: What’s Next for Purification and Workforce Development?

Kingston’s work isn’t just about refining existing processes; it’s about enabling the development of entirely new therapies. As she puts it, “We are drugging the undruggable now.” This ambition requires increasingly sophisticated analytical techniques and a highly skilled workforce. Expect to see increased investment in SFC and other ‘green’ chemistry technologies as pharmaceutical companies strive to meet sustainability goals and reduce costs.

More broadly, AstraZeneca’s apprenticeship model is likely to be replicated by other companies in the sector. The program’s success provides a compelling case study for government initiatives aimed at bolstering STEM education and workforce development. We can anticipate a growing emphasis on collaborative partnerships between industry and academia to create more apprenticeship opportunities and ensure that the next generation of scientists is equipped to tackle the challenges of tomorrow. The Royal Society of Chemistry’s recognition of Kingston’s achievements isn’t just a celebration of past success; it’s a signal of the priorities that will shape the future of pharmaceutical innovation.